Diabetic Retinopathy Market

LAS VEGAS, NEVADA, UNITED STATES, March 26, 2024 /EINPresswire.com/ -- DelveInsight's " Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Diabetic Retinopathy, historical and forecasted epidemiology as well as the Diabetic Retinopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Takeaways from the Diabetic Retinopathy Market Research Report
• The current understanding of Diabetic Retinopathy has greatly improved in recent decades, leading to growing awareness, improved management, and better outcomes.
• According to secondary research by analysts at DelveInsight, it is estimated that the prevalence of DR is slightly higher in males as compared to females.
• The leading Diabetic Retinopathy Companies working in the market include Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, and others.
• Promising Diabetic Retinopathy Pipeline Therapies in the various stages of development include OPT-302, RGX 314, KSI-301, APX3330, OCS-01, Runcaciguat (BAY 1101042), Brolucizumab, LKA651, Risuteganib, ADVM-022, GB-102, Emixustat Hydrochloride, KVD001, RG7774, and others.
• March 2024: Aviceda Therapeutics Inc. announced a study of Phase 2 clinical trials for AVD-104. A Phase 2 study to determine the safety and preliminary efficacy of intravitreal injections of AVD-104, a novel glyco-mimetic nanoparticle, in reducing macular edema associated with diabetic retinopathy.
• March 2024: Novartis Pharmaceuticals announced a study of Phase 3 clinical trials for Brolucizumab 6 mg and Panretinal photocoagulation laser. The purpose of this study is to evaluate the efficacy and safety of brolucizumab compared to panretinal photocoagulation laser (PRP) in patients with proliferative diabetic retinopathy (PDR). This evaluation will provide information that brolucizumab is non-inferior to PRP with respect to the change in best corrected visual acuity at Week 54.

Discover which therapies are expected to grab the Diabetic Retinopathy market share @ Diabetic Retinopathy Market Outlook

Diabetic Retinopathy Overview
Diabetic retinopathy is a micro vascular disorder occurring due to long term effects of diabetes, leading to vision-threatening damage to the retina, eventually leading to blindness. Diabetic retinopathy affects people with diagnosed or undiagnosed diabetes mellitus. The propensity of developing diabetic retinopathy is directly proportional to the age of the patient and duration of diabetes as well as with poor glycemic control and fluctuation blood pressure level.

Diabetic Retinopathy Epidemiology Segmentation in the 7MM
• Total Diabetic Retinopathy Prevalent Cases
• Diabetic Retinopathy Gender-Specific Prevalent Cases
• Diabetic Retinopathy Severity-Specific Prevalent Cases
• Diabetic Retinopathy Age-Specific Prevalent Cases

Download the report to understand which factors are driving Diabetic Retinopathy epidemiology trends @ Diabetic Retinopathy Epidemiological Insights

Diabetic Retinopathy Drug Market
The therapeutic interventions is classified into several intravitreal anti-VEGF drugs. Anti-VEGF drugs are preferred as the first line of therapy. They work by blocking the production of new blood vessels and reducing macular swelling. This slows vision loss and improves vision. These agents are administered via intravitreal injections into the eye. These include aflibercept (EYLEA from Regeneron and Bayer), ranibizumab (LUCENTIS from Genentech and Novartis), and Faricimab (VABYSMO from Genentech, Inc. / Roche) dominates the diabetic retinopathy market.

Diabetic Retinopathy Drugs Uptake
OPT-302 is a promising therapeutic agent for Diabetic Retinopathy (DR), designed to address the vascular complications associated with this condition. As a soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR-2) protein, OPT-302 works by inhibiting the activity of multiple VEGF isoforms, thereby disrupting the pathological angiogenesis and vascular permeability characteristic of DR. By targeting key pathways involved in the progression of the disease, OPT-302 holds the potential to mitigate vision-threatening consequences, offering a novel and targeted approach in the management of Diabetic Retinopathy. It has completed Phase Ib/IIa of its clinical development.

RGX-314 is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions. RGX-314 consists of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF). RGX-314 is believed to inhibit the VEGF pathway by which new, leaky blood vessels grow and contribute to the fluid accumulation in the retina. It is currently in Phase II of its clinical development.

Tarcocimab tedromer (KSI-301) is a novel anti-VEGF biologic built on a propriety antibody biopolymer conjugate (ABC) platform. KSI301 is given as an intravitreal injection and is expected to inhibit VEGF for up to 6 months continuously. The unique properties of KSI 301 are intended to provide patients with long-term control of DME and improve visual results while reducing the burden of frequent anti-VEGF injections. In addition, KSI301 is designed to prevent and reverse the progression of DR with long-term efficacy and may reduce the risk of vision-threatening complications from DR. It is currently in Phase III of its clinical development.

Diabetic Retinopathy Treatment Landscape
Diabetic Retinopathy treatments for diabetic retinopathies are limited, and the focus relies heavily on the presence of macular edema. Historically, traditional therapies such as vitrectomy, photocoagulation, and corticosteroids were used. These offer no opportunity for vision improvement and come with high rates of complications. On other hand Anti-vascular endothelial growth factor (anti-VEGF) drugs have made a meaningful improvement to DME sufferers over the past decade, but even these have limited to no success in third or more sufferers. Three anti-VEGF drugs are preferred as the first line of therapy. They work by blocking the production of new blood vessels and reducing macular swelling. This slows vision loss and improves vision. These agents are administered via injections into the eye. These include aflibercept (EYLEA from Regeneron and Bayer), ranibizumab (LUCENTIS from Genentech and Novartis), and bevacizumab (AVASTIN from Genentech); these dominate the diabetic retinopathy market.

Diabetic Retinopathy Market Dynamics
The diabetic retinopathy market dynamics are expected to change in the coming years. Various pathways have been thoroughly investigated as potential causes of the disease, leading to a deeper understanding after years of research and development. The presence of a substantial patient population enables companies to develop cost-effective drugs and achieve significant profits.

Scope of the Diabetic Retinopathy Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Diabetic Retinopathy Companies- Genentech, Inc., Regeneron Pharmaceuticals, Roche, Opthea Limited, Regenxbio, Kodiak Sciences Inc, Allegro Ophthalmics, LLC, Adverum Biotechnologies, Inc., Graybug Vision, and others.
• Diabetic Retinopathy Pipeline Therapies- OPT-302, RGX 314, KSI-301, APX3330, OCS-01, Runcaciguat (BAY 1101042), Brolucizumab, LKA651, Risuteganib, ADVM-022, GB-102, Emixustat Hydrochloride, KVD001, RG7774, and others.
• Diabetic Retinopathy Market Dynamics: Diabetic Retinopathy Market Drivers and Barriers

Discover more about Diabetic Retinopathy Drugs in development @ Diabetic Retinopathy Ongoing Clinical Trials Analysis

Table of Content
1. Key Insights
2. Report Introduction
3. Diabetic Retinopathy Market Overview at a Glance
4. Executive Summary of Diabetic Retinopathy
5. Disease Background and Overview
6. Management and Treatment
7. Epidemiology and Patient Population
8. Patient Journey 1
9. Patient Journey 2
10. Marketed Drugs
12. Other Therapy
13. Diabetic Retinopathy: Seven Major Market Analysis
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj
DelveInsight
+91 9650213330
ybhardwaj@delveinsight.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.